TABLE OF CONTENTS
1 INTRODUCTION 116
1.1 OBJECTIVES OF THE STUDY 116
1.2 MARKET DEFINITION 116
1.3 OVERVIEW OF THE EUROPE MEDICAL AESTHETICS MARKET 116
1.4 LIMITATIONS 119
1.5 MARKETS COVERED 120
2 MARKET SEGMENTATION 128
2.1 MARKETS COVERED 128
2.2 GEOGRAPHICAL SCOPE 129
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 CURRENCY AND PRICING 129
2.5 DBMR TRIPOD DATA VALIDATION MODEL 130
2.6 MULTIVARIATE MODELLING 133
2.7 PROCEDURE LIFELINE CURVE 133
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.9 DBMR MARKET POSITION GRID 135
2.10 MARKET END USER COVERAGE GRID 136
2.11 SECONDARY SOURCES 137
2.12 ASSUMPTIONS 137
3 EXECUTIVE SUMMARY 138
4 PREMIUM INSIGHTS 141
4.1 PESTEL ANALYSIS 142
4.2 PORTERS FIVE FORCES 143
4.3 KEY TREND IN THE EUROPE MEDICAL AESTHETICS MARKET 144
5 INDUSTRY INSIGHT 146
6 EPIDEMIOLOGY 147
6.1 NUMBER OF COSMETIC PROCEDURES, BY COUNTRY 147
6.1.1 GERMANY 147
6.1.2 ITALY 148
6.1.3 SPAIN 148
6.1.4 ROMANIA 149
6.1.5 U.K. 150
6.2 RECONSTRUCTION PROCEDURES 151
6.2.1 RECONSTRUCTION PROCEDURE IMPROVES FORM AND FUNCTION 151
6.2.2 EXAMPLES OF RECONSTRUCTIVE SURGERY INCLUDE: 151
6.2.3 RECONSTRUCTIVE SURGERY RISKS AND RECOVERY 151
6.2.4 IMMEDIATE AND DELAYED BREAST RECONSTRUCTION 151
6.2.5 STRUCTURE OF CARE, EQUITY AND ACCESS TO BREAST RECONSTRUCTION ACROSS EUROPEAN COUNTRIES 151
6.2.6 LIP RECONSTRUCTION SURGERY 152
6.2.7 DEFECTS 152
7 REGULATORY FRAMEWORK 153
8 MARKET OVERVIEW 154
8.1 DRIVERS 156
8.1.1 RISING PREVALENCE OF MINIMALLY INVASIVE PROCEDURES 156
8.1.2 INCREASING AWARENESS TOWARDS COSMETIC SURGERIES 156
8.1.3 RISE IN MEDICAL TOURISM IN EUROPE 157
8.1.4 BELIEFS AND TRENDS OF AESTHETIC SURGERY IN YOUNG ADULTS 157
8.1.5 INCREASING RESEARCH AND DEVELOPMENT IN THE MEDICAL AESTHETICS INDUSTRY 158
8.2 RESTRAINTS 159
8.2.1 STRINGENT REGULATORY FRAMEWORK 159
8.2.2 SIDE EFFECTS RELATED TO AESTHETIC PROCEDURES 159
8.3 OPPORTUNITIES 160
8.3.1 GROWING TECHNOLOGICAL ADVANCEMENTS AND DEVELOPMENTS 160
8.3.2 INCREASING FUNDING ACTIVITIES FOR AESTHETIC RESEARCH 161
8.4 CHALLENGES 161
8.4.1 LACK OF SKILLED PROFESSIONALS 161
8.4.2 LONG APPROVAL TIME ASSOCIATED WITH PRODUCT LAUNCH 161
9 EUROPE MEDICAL AESTHETICS MARKET, BY PRODUCTS 163
9.1 OVERVIEW 164
9.2 NON-ENERGY BASED AESTHETICS DEVICES 167
9.3 ENERGY - BASED MEDICAL AESTHETICS 167
10 EUROPE MEDICAL AESTHETICS MARKET, BY RAW MATERIAL 168
10.1 OVERVIEW 169
10.2 POLYMERS 172
10.3 METALS 172
10.4 CERAMICS 173
10.5 SILICON 173
10.6 RESIN COMPOSITES 173
10.7 TITANIUM 174
10.8 OTHERS 174
11 EUROPE MEDICAL AESTHETICS MARKET, BY PROCEDURE 175
11.1 OVERVIEW 176
11.2 COSMETIC PROCEDURE 179
11.3 RECONSTRUCTION PROCEDURE 179
12 EUROPE MEDICAL AESTHETICS MARKET, BY PATIENT TYPE 180
12.1 OVERVIEW 181
12.2 FEMALE 184
12.3 MALE 184
13 EUROPE MEDICAL AESTHETICS MARKET, BY END USER 185
13.1 OVERVIEW 186
13.2 DERMATOLOGY CLINICS 189
13.3 COSMETIC CENTERS 189
13.4 HOSPITAL 190
13.5 CLINICS 190
13.6 MEDICAL SPAS AND BEAUTY CENTERS 191
13.7 HOMECARE 191
13.8 ACADEMIC AND RESEARCH INSTITUTES 191
13.9 OTHERS 192
14 EUROPE MEDICAL AESTHETICS MARKET, BY DISTRIBUTION CHANNEL 193
14.1 OVERVIEW 194
14.2 DIRECT TENDER 197
14.3 RETAIL SALES 197
14.4 OTHERS 198
15 EUROPE MEDICAL AESTHETICS MARKET 199
15.1 EUROPE 199
15.1.1 GERMANY 239
15.1.2 U.K. 286
15.1.3 FRANCE 332
15.1.4 ITALY 378
15.1.5 RUSSIA 424
15.1.6 SPAIN 470
15.1.7 NETHERLANDS 515
15.1.8 BELGIUM 560
15.1.9 LUXEMBOURG 605
15.1.10 SWITZERLAND 649
15.1.11 TURKEY 694
15.1.12 REST OF EUROPE 740
16 EUROPE MEDICAL AESTHETICS MARKET: COMPANY LANDSCAPE 741
16.1 COMPANY SHARE ANALYSIS: EUROPE 741
17 SWOT ANALYSIS 742
18 COMPANY PROFILE 743
18.1 MENTOR WORLDWIDE LLC (A SUBSIDIARY OF JOHNSONS & JOHNSONS) 743
18.1.1 COMPANY SNAPSHOT 743
18.1.2 REVENUE ANALYSIS 744
18.1.3 PRODUCT PORTFOLIO 744
18.1.4 RECENT DEVELOPMENT 745
18.2 GALDERMA 746
18.2.1 COMPANY SNAPSHOT 746
18.2.2 PRODUCT PORTFOLIO 746
18.2.3 RECENT DEVELOPMENTS 746
18.3 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 747
18.3.1 COMPANY SNAPSHOT 747
18.3.2 REVENUE ANALYSIS 747
18.3.3 PRODUCT PORTFOLIO 748
18.3.4 RECENT DEVELOPMENT 748
18.4 DENTSPLY SIRONA. 749
18.4.1 COMPANY SNAPSHOT 749
18.4.2 REVENUE ANALYSIS 749
18.4.3 PRODUCT PORTFOLIO 750
18.4.4 RECENT DEVELOPMENT 750
18.5 INSTITUT STRAUMANN AG 751
18.5.1 COMPANY SNAPSHOT 751
18.5.2 REVENUE ANALYSIS 751
18.5.3 PRODUCT PORTFOLIO 752
18.5.4 RECENT DEVELOPMENT 752
18.6 3M 753
18.6.1 COMPANY SNAPSHOT 753
18.6.2 REVENUE ANALYSIS 753
18.6.3 PRODUCT PORTFOLIO 754
18.6.4 RECENT DEVELOPMENT 754
18.7 ALMA LASERS 755
18.7.1 COMPANY SNAPSHOT 755
18.7.2 PRODUCT PORTFOLIO 755
18.7.3 RECENT DEVELOPMENTS 756
18.8 BTL 757
18.8.1 COMPANY SNAPSHOT 757
18.8.2 PRODUCT PORTFOLIO 757
18.8.3 RECENT DEVELOPMENT 758
18.9 BIOHORIZONS 759
18.9.1 COMPANY SNAPSHOT 759
18.9.2 PRODUCT PORTFOLIO 759
18.9.3 RECENT DEVELOPMENTS 759
18.10 CANDELA CORPORATION 760
18.10.1 COMPANY SNAPSHOT 760
18.10.2 PRODUCT PORTFOLIO 760
18.10.3 RECENT DEVELOPMENTS 760
18.11 CUTERA 761
18.11.1 COMPANY SNAPSHOT 761
18.11.2 REVENUE ANALYSIS 761
18.11.3 PRODUCT PORTFOLIO 762
18.11.4 RECENT DEVELOPMENT 762
18.12 CYNOSURE 763
18.12.1 COMPANY SNAPSHOT 763
18.12.2 PRODUCT PORTFOLIO 763
18.12.3 RECENT DEVELOPMENTS 763
18.13 LUMENIS BE LTD. 764
18.13.1 COMPANY SNAPSHOT 764
18.13.2 PRODUCT PORTFOLIO 764
18.13.3 RECENT DEVELOPMENTS 764
18.14 MEDYTROX 765
18.14.1 COMPANY SNAPSHOT 765
18.14.2 PRODUCT PORTFOLIO 765
18.14.3 RECENT DEVELOPMENTS 765
18.15 MERZ PHARMA 766
18.15.1 COMPANY SNAPSHOT 766
18.15.2 PRODUCT PORTFOLIO 766
18.15.3 RECENT DEVELOPMENTS 766
18.16 MEGA'GEN IMPLANT CO., LTD. 768
18.16.1 COMPANY SNAPSHOT 768
18.16.2 PRODUCT PORTFOLIO 768
18.16.3 RECENT DEVELOPMENTS 768
18.17 NOBEL BIOCARE SERVICES AG 769
18.17.1 COMPANY SNAPSHOT 769
18.17.2 PRODUCT PORTFOLIO 769
18.17.3 RECENT DEVELOPMENTS 769
18.18 QUANTA SYSTEM 770
18.18.1 COMPANY SNAPSHOT 770
18.18.2 PRODUCT PORTFOLIO 770
18.18.3 RECENT DEVELOPMENT 770
18.19 SCITON 771
18.19.1 COMPANY SNAPSHOT 771
18.19.2 PRODUCT PORTFOLIO 771
18.19.3 RECENT DEVELOPMENT 771
18.20 SHARPLIGHT TECHNOLOGIES INC. 772
18.20.1 COMPANY SNAPSHOT 772
18.20.2 PRODUCT PORTFOLIO 772
18.20.3 RECENT DEVELOPMENTS 773
19 QUESTIONNAIRE 774
20 RELATED REPORTS 778

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.